About the Company
alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
57
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALXO News
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno ...
ALX Oncology Holdings Inc Ordinary Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ALX Oncology (NASDAQ: ALXO)
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for ...
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral ...
ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
Warning! GuruFocus has detected 4 Warning Signs with ALXO. On March 7, 2024, ALX Oncology Holdings Inc (NASDAQ:ALXO) released its 8-K filing, detailing the financial results for the fourth quarter ...
ALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment Studies
LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ALXO stock, giving a Buy rating today. Sam Slutsky has given his Buy rating due to a combination of factors that ...
ALX Oncology Holdings Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an ...
ALXO ALX Oncology Holdings Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno ...
Loading the latest forecasts...